Gabriel Levesque Tremblay, Ph.D.Founder

United States - New York, New York

Gabriel Levesque Tremblay, PhD is a biotechnology entrepreneur and leader in synthetic biology and longevity, focused on translating frontier science into clinical impact. He is the Founder and CEO of HexemBio, a company pioneering the breakthrough blood stem cell rejuvenation therapy. The company’s platform, published in Nature and featured in The New York Times and on NASDAQ, has received FDA Orphan Drug Designation, and successfully completed a Pre-IND meeting, positioning it for first-in-human studies.

A two-time founder with one exit and a Y Combinator alumnus, Gabriel has secured more than $100 million in competitive funding from the NSF, NIH, DOE, and DoD. His work spans synthetic biology, regenerative engineering, AI-driven biotechnology, and dual-use defense applications. He has helped establish major scientific initiatives including the Regenerative Engineering Society, CRISPR Technologies, Stem Cell Engineering, and AI for Biotechnology (NSF).

Gabriel completed his postdoctoral training at UC Berkeley and earned his Ph.D. from the University of British Columbia as a federal scholarship recipient. His career bridges deep science, regulatory strategy, and venture-scale company building with a focus on redefining aging at its biological root.

To learn more, visit hexemb.io.